| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/03/2008 | EP1328289B1 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof |
| 09/03/2008 | EP1311708B1 Method for identifying substances useful for treating inflammation using the response element to the ikappabaplha ror receptor |
| 09/03/2008 | EP1253943B1 Photodynamic therapy for treating conditions of the eye |
| 09/03/2008 | EP1192279B1 Diagnostics for fragile plaque disorder |
| 09/03/2008 | EP1180159B1 Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders |
| 09/03/2008 | EP1131070B1 Pharmaceutical composition for modified release of an insulin sensitiser and metformin |
| 09/03/2008 | EP1121129B1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS |
| 09/03/2008 | EP0789575B1 Peripheral nervous system specific sodium channels, dna encoding therefor, drug screening, and methods of making and using thereof |
| 09/03/2008 | EP0710116B1 Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
| 09/03/2008 | CN101258166A Antibody combining with STEAP-1 protein and deriving molecule thereof |
| 09/03/2008 | CN101257946A Pharmaceutical dosage form containing an active principle combination of nifedipine and/or nisoldipine and of an angiotensin ii antagonist |
| 09/03/2008 | CN101257924A Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents |
| 09/03/2008 | CN101257904A Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist |
| 09/03/2008 | CN101257899A Treatment of autoimmune diseases |
| 09/03/2008 | CN101255192A Soluble CTLA4 mutant molecules and uses thereof |
| 09/03/2008 | CN101254310A Applications human neuro nutriment-3 receptor gene recombination ad virus for preparing medicine treating nerve injury |
| 09/03/2008 | CN101254309A Folacin receptor mediated targeted acetyl pullulan polysaccharide nano granule and preparation thereof |
| 09/03/2008 | CN101254308A Biogastrone acid-polyethyleneglycol /chitosan liver target composite drug administration system and preparation thereof |
| 09/03/2008 | CN101254305A Composite nasal cavity preparations for curing allergic rhinitis |
| 09/03/2008 | CN101254304A Medicaments for treating micro-organism infection and use thereof |
| 09/03/2008 | CN101254181A Hypertension-treating medicine combination |
| 09/03/2008 | CN101254170A An anticancer sustained release injection carrying clorfarabine and its synergist |
| 09/03/2008 | CN101254166A An anticancer sustained release injection carrying clorfarabine and its synergist |
| 09/03/2008 | CN100415772C Anti-ErbB2 antibodies |
| 09/03/2008 | CN100415296C Compositions containing inclusion complexes |
| 09/03/2008 | CN100415247C Strontium compound for treatment of sub-dermal soft tissue pain |
| 09/03/2008 | CN100415235C Medicinal composition containing an HMG-CoA reductase inhibitor |
| 09/03/2008 | CN100415227C Use of compounds in preparing medicament for treating treating transplant rejection |
| 09/03/2008 | CN100415223C Controlled releasing oral medicine composition |
| 09/03/2008 | CN100415222C Methods of using and compositions comprising dopamine reuptake inhibitors |
| 09/03/2008 | CN100415219C Substituted bicyclo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients |
| 09/03/2008 | CN100415217C Uses of adenosine A2A receptor antagonists |
| 09/03/2008 | CN100415216C Timed dual release dosage forms comprising short acting hypnotic or salt thereof |
| 09/03/2008 | CN100415188C Condom with erectogenic composition |
| 09/02/2008 | US7420100 Animal model lacking histone deacetylase (HDAC) for use as diagnostic tool in detection, diagnosis and prevention of cardiac hypertrophy |
| 09/02/2008 | US7420089 for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition |
| 09/02/2008 | US7420085 Form II; used for facilitating the delivery of active agents, such as insulin, to a target |
| 09/02/2008 | US7420037 Heat shock protein-based vaccines and immunotherapies |
| 09/02/2008 | US7420029 A tissue-specific transporter function inhibitor has both a ligand structure recognized by a tissue-specific transporter and a polymeric molecular structure incapable of passing through a membrane tissue |
| 09/02/2008 | US7419971 Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application |
| 09/02/2008 | US7419968 Screening for anticancer drugs for treating cells that endogenously overexpress intracellular thymidylate synthase by contacting the cell with the candidate and (E)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl phenyl L-alaninylphosphoramidate and assaying for cell death |
| 09/02/2008 | US7419966 Viricides; human t-cell leukemia, lymphoma virus |
| 09/02/2008 | US7419952 Use of exendins and agonists thereof to treat diabetes |
| 09/02/2008 | US7419814 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
| 09/02/2008 | US7419799 Medical diagnosis; gene expression; genetic engineering; cell proliferation |
| 09/02/2008 | US7419794 Antibodies specific for CYP1B1 |
| 09/02/2008 | US7419793 Flea octopamine receptor nucleic acid molecules, proteins and uses thereof |
| 09/02/2008 | US7419790 Sodium-independent transporter carrying acidic amino acid and its gene |
| 09/02/2008 | US7419686 For preventing oral abuse of an oral opioid formulation; provides a negative, "aversive" experience when a large amount of the opioid, e.g., about 2-3 times the usually prescribed dose, is taken by or administered to a physically dependent subject |
| 09/02/2008 | US7419678 Coated medical devices for the prevention and treatment of vascular disease |
| 09/02/2008 | US7419670 Method of treating arthritis with SERP-1 and an immunosuppressant |
| 09/02/2008 | CA2466728C Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1 |
| 09/02/2008 | CA2389333C Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 09/02/2008 | CA2384922C Topical glycopyrrolate product for the reduction of sweating |
| 09/02/2008 | CA2372053C Compositions and methods for cancer treatment by selectively inhibiting vegf |
| 09/02/2008 | CA2356158C Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 09/02/2008 | CA2351068C Drug delivery device, especially for the delivery of progestins and estrogens |
| 09/02/2008 | CA2325818C Topical immunostimulation to induce langerhans cell migration |
| 09/02/2008 | CA2292910C Hair growth compositions and uses |
| 09/02/2008 | CA2276269C N-acyl phosphatidylethanolamine-mediated liposomal drug delivery |
| 09/02/2008 | CA2271244C Pressure-mediated intracellular delivery of molecules or microparticles |
| 09/02/2008 | CA2246430C Protein tyrosine phosphatases of hematopoietic cells |
| 09/02/2008 | CA2232527C Anti-inflammatory agent |
| 08/28/2008 | WO2008103301A2 Treatment of the eye using macrophages and/or agents able to affect blood vessel morphology |
| 08/28/2008 | WO2008102912A1 Target protein and target gene for drug discovery, and screening method |
| 08/28/2008 | WO2008102783A1 Hair regrowth promoter |
| 08/28/2008 | WO2008102777A1 Ameliorating agent for insulin resistance |
| 08/28/2008 | WO2008102128A2 Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
| 08/28/2008 | WO2008101354A1 Gpr65 as a therapeutic target in allergic airway inflammation |
| 08/28/2008 | WO2008101344A1 Soluble bioactive lipophilic compounds compositions |
| 08/28/2008 | WO2008079312A3 Compositions for treatment of nasal congestion |
| 08/28/2008 | WO2008079256A3 Methods for treating nasal congestion in hypertensive or diabetic patients |
| 08/28/2008 | WO2008063513A3 Selective proteasome inhibitors for treating diabetes |
| 08/28/2008 | WO2008047364A3 Method and pharmacological composition for the diagnosis and treatment of male sub-fertility |
| 08/28/2008 | WO2007149410A3 Powder exfoliating compositions and methods for producing the same |
| 08/28/2008 | WO2007134136A3 Neurogenesis by modulating angiotensin |
| 08/28/2008 | US20080209581 Induction of exon skipping in eukaryotic cells |
| 08/28/2008 | US20080208167 Methods and compositions to treat myocardial conditions |
| 08/28/2008 | US20080207763 Synergistic mixture of analgesics and endothelin antagonist; fever therapy |
| 08/28/2008 | US20080207730 Methods of using (+)-2-[1-(3-Ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
| 08/28/2008 | US20080207653 Antitumor agents |
| 08/28/2008 | US20080207600 Pharmaceutical Combination for the Treatment of Cns Functional Disorders |
| 08/28/2008 | US20080207580 Method of treating immune pathologies with low dose estrogen |
| 08/28/2008 | US20080207537 Reducing agent and oxidizing agent are separately disposed and sequentially administered to a nail; oxidizer increases permeability; thioglycolic acid derivative and hydrogen peroxide; psoriasis; fungicides |
| 08/28/2008 | US20080207524 Medicinal preparations for treating sex hormone-dependent diseases |
| 08/28/2008 | US20080207516 Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 08/28/2008 | US20080206736 Administering a therapeutically effective amount of a flavin N-oxide; exposing flavin N-oxide to an activator, such that activation of the flavin N- oxide results in damage to the DNA in cancer cells without damage to the DNA in normal cells |
| 08/28/2008 | US20080206336 Once-a-day modified release tablet formulation rosiglitazone and metformin; enteric coating to control the rate of release; erosion of coating under pre-determined pH conditions; diabetes mellitus, metabolic syndrome, impaired glucose tolerance or impaired fasting glucose |
| 08/28/2008 | US20080206326 Liquid salt of a non-steroidal anti-inflammatory drug, flurbiprofen; propylene glycol solvent; sucrose, glucose, sorbitol, xylitol, maltitol, a hydrogenated starch hydrosylate, molten lozenge-forming composition; sore throats |
| 08/28/2008 | US20080206309 Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorrhagia |
| 08/28/2008 | US20080206284 E. coli heat-labile enterotoxin that binds to GM1 ganglioside receptors; allergic rhinitis |
| 08/28/2008 | US20080206269 stimulate the resuscitation of bacteria after true dormancy; cognate receptors, convertases, respective genes and inhibitors or mimetics |
| 08/28/2008 | US20080206266 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 08/28/2008 | US20080206257 Reducing epithelial toxicity during cancer therapy by administering KGF with e.g. erlotinib, Iressa(TM), canertinib, or a monoclonal antibody against EGFR; side effect reduction of diarrhea, rash |
| 08/28/2008 | US20080206256 Treatments for cancer |
| 08/28/2008 | US20080206252 Novel Polypeptides, and Nucleic Acids Encoding the Same |
| 08/28/2008 | US20080206224 Muscle contraction treatment utilizing botulinum toxin |
| 08/28/2008 | US20080206193 Angiogenesis inhibitors; immunomodulators; side effect reduction |
| 08/28/2008 | US20080206190 Glycosylated IL-7, Preparation And Uses |
| 08/28/2008 | US20080206189 Using water-soluble polymer conjugated interleukin-18 as therapeutic in treatment and prevention of cell proliferative disorders |